The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
BACKGROUND Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents. METHODS Within the multicenter Pharmacokinetics of ANtiretroviral agents in HIV infected pregNAnt women (PANNA) study, pregnant women living with HIV and using dolutegravir once daily (50 mg, with food) underwent 24 hour pharmacokinetic profiling in their third trimester and postpartum. Dolutegravir exposure in the third trimester was considered adequate if geometric mean unbound, pharmacologically active, minimal plasma concentrations (Cmin, unbound) and =90% of individual Cmin, unbound levels were >0.85 ug/L, the proposed 90% inhibitory concentration for unbound dolutegravir. Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) for comparison of total and unbound pharmacokinetic parameters in the third trimester and postpartum were calculated, including the metabolic ratio for dolutegravir glucuronide. Safety and virological data were collected. RESULTS Seventeen women (76% black) were enrolled (25 evaluable pharmacokinetic profiles; 15 in the third trimester, 10 in postpartum) In the third trimester, geometric mean (coefficient of variation, Cmin, unbound was 2.87 (87) ug/L and 93% of individual Cmin, unbound levels were >0.85 ug/L. The GMR (90% CI) in the third trimester vs postpartum was 0.86 .68 1.10) for area under the curve (AUC0 24h) and for Cmax, 0.93 .77 1.13) GMR (90% CI) for the trough concentrations was 0.71 .49 1.02) based on total dolutegravir concentrations. Four serious adverse events were reported, unlikely related to dolutegravir. The HIV polymerase chain reaction test was negative in 14/17 infants (result unknown for 3 infants) CONCLUSIONS Pharmacokinetic changes for dolutegravir in late pregnancy are not clinically relevant and support the use of dolutegravir 50 mg once daily with food in pregnancy. CLINICAL TRIALS REGISTRATION NCT00825929.
Clinical infectious diseases an official publication of the Infectious Diseases Society of America